Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Beam me up Scotty

<< Previous

Bullboard Posts

Next >>

Comment by Dude51on Feb 16, 2021 11:36am

180 Views

Post# 32573497

RE:RE:RE:Beam me up Scotty

Scotty - (2/16/2021 9:20:34 AM)
RE:RE:Beam me up Scotty

You pumpers are really dense. Everything needs to be drawn in crayon for you guys. When have I ever denied the science? I'm knocking the company for being a shell. Period.
---------------------------------------------------

Where is your proof? give us a link, just one yhat proves your shell theory?

Scotty - (2/16/2021 9:20:34 AM)
RE:RE:Beam me up Scotty

You pumpers are really dense. Everything needs to be drawn in crayon for you guys. When have I ever denied the science? I'm knocking the company for being a shell. Period.

<< Previous

Bullboard Posts

Next >>

Drilling underway at a large copper-moly porphyry target in Peru